Pharmacogenetic tests: The need for a level playing field

Nature Reviews Drug Discovery

Volumn 12, Issue 1, 2013, Pages 3-4

  Pirmohamed, Munir ^a   Hughes, Dyfrig A ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AZTREONAM; CARBAMAZEPINE; CYTOCHROME P450 2D6; HLA B ANTIGEN; ORPHAN DRUG;

COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG COST; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG METABOLISM; DRUG RESPONSE; GENETIC POLYMORPHISM; GENETIC SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; MEDICAL TECHNOLOGY; PERSONALIZED MEDICINE; PHARMACOGENETIC TEST; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; STEVENS JOHNSON SYNDROME;

DRUG DESIGN; DRUG LABELING; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC; REIMBURSEMENT MECHANISMS;

EID: 84871880318     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3921     Document Type: Review

References (5)

1. Sauer, J. M., Ring, B. J. & Witcher, J. W. Clinical pharmacokinetics of atomoxetine. Clin. Pharmacokinet. 44, 571-590 (2005). (Pubitemid 40994086)
2. Ciszkowski, C., Madadi, P., Phillips, M. S., Lauwers, A. E. & Koren, G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N. Engl. J. Med. 361, 827-828 (2009).
3. Zineh, I. et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 12, 1741-1749 (2011).
4. Mallal, S. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358, 568-579 (2008). (Pubitemid 351214284)
5. Chen, P. et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364, 1126-1133 (2011).